Which has preferable valuation & earnings, BVS or SMTI?

Bioventus has higher revenue and earnings than Sanara MedTech. Sanara MedTech is trading at a lower price-to-earnings ratio than Bioventus, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Bioventus $568.09M 1.25 $22.73M $0.41 20.76 Sanara MedTech $103.12M 1.85 -$37.56M -$3.77 N/A

Does the media favor BVS or SMTI?

In the previous week, Bioventus and Bioventus both had 4 articles in the media. Sanara MedTech's average media sentiment score of 1.19 beat Bioventus' score of 1.00 indicating that Sanara MedTech is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bioventus 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Sanara MedTech 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to SMTI or SSII?

In the previous week, Sanara MedTech had 2 more articles in the media than SS Innovations International. MarketBeat recorded 4 mentions for Sanara MedTech and 2 mentions for SS Innovations International. Sanara MedTech's average media sentiment score of 1.19 beat SS Innovations International's score of 1.16 indicating that Sanara MedTech is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sanara MedTech 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SS Innovations International 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation and earnings, SMTI or CBLL?

Sanara MedTech has higher revenue and earnings than CeriBell. CeriBell is trading at a lower price-to-earnings ratio than Sanara MedTech, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Sanara MedTech $103.12M 1.85 -$37.56M -$3.77 N/A CeriBell $89.06M 7.87 -$53.41M -$1.63 N/A

Is SMTI or CBLL more profitable?

Sanara MedTech has a net margin of -31.23% compared to CeriBell's net margin of -63.51%. Sanara MedTech's return on equity of -3.19% beat CeriBell's return on equity. Company Net Margins Return on Equity Return on Assets Sanara MedTech -31.23% -3.19% -0.56% CeriBell -63.51% -38.19% -30.92%

Does the media refer more to SMTI or CBLL?

In the previous week, CeriBell had 1 more articles in the media than Sanara MedTech. MarketBeat recorded 5 mentions for CeriBell and 4 mentions for Sanara MedTech. Sanara MedTech's average media sentiment score of 1.19 beat CeriBell's score of 0.56 indicating that Sanara MedTech is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sanara MedTech 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive CeriBell 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings & valuation, SIBN or SMTI?

SiBone has higher revenue and earnings than Sanara MedTech. SiBone is trading at a lower price-to-earnings ratio than Sanara MedTech, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio SiBone $200.93M 3.40 -$18.90M -$0.39 N/A Sanara MedTech $103.12M 1.85 -$37.56M -$3.77 N/A

Is SIBN or SMTI more profitable?

SiBone has a net margin of -8.10% compared to Sanara MedTech's net margin of -31.23%. Sanara MedTech's return on equity of -3.19% beat SiBone's return on equity. Company Net Margins Return on Equity Return on Assets SiBone -8.10% -9.56% -7.06% Sanara MedTech -31.23% -3.19% -0.56%

Does the media favor SIBN or SMTI?

In the previous week, Sanara MedTech had 1 more articles in the media than SiBone. MarketBeat recorded 4 mentions for Sanara MedTech and 3 mentions for SiBone. Sanara MedTech's average media sentiment score of 1.19 beat SiBone's score of 0.60 indicating that Sanara MedTech is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment SiBone 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Sanara MedTech 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to SMTI or BBNX?

In the previous week, Beta Bionics had 2 more articles in the media than Sanara MedTech. MarketBeat recorded 6 mentions for Beta Bionics and 4 mentions for Sanara MedTech. Sanara MedTech's average media sentiment score of 1.19 beat Beta Bionics' score of 0.22 indicating that Sanara MedTech is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sanara MedTech 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Beta Bionics 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Sanara MedTech (SMTI) Competitors

$20.81 0.00 (0.00%)

Closing price 06/12/2026 04:00 PM Eastern

Extended Trading

$21.52 +0.72 (+3.44%)

As of 06/12/2026 04:29 PM Eastern

Compare

SMTI vs. BVS, SSII, CBLL, SIBN, and BBNX

Should you buy Sanara MedTech stock or one of its competitors? MarketBeat compares Sanara MedTech with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Sanara MedTech include Bioventus (BVS), SS Innovations International (SSII), CeriBell (CBLL), SiBone (SIBN), and Beta Bionics (BBNX). These companies are all part of the "medical equipment" industry.

How does Sanara MedTech compare to Bioventus?

Bioventus (NASDAQ:BVS) and Sanara MedTech (NASDAQ:SMTI) are both small-cap medical equipment companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, risk, profitability, dividends, valuation, media sentiment, analyst recommendations and institutional ownership.

Bioventus has a net margin of 4.94% compared to Sanara MedTech's net margin of -31.23%. Bioventus' return on equity of 29.97% beat Sanara MedTech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bioventus	4.94%	29.97%	9.52%
Sanara MedTech	-31.23%	-3.19%	-0.56%

Bioventus currently has a consensus target price of $14.00, suggesting a potential upside of 64.51%. Sanara MedTech has a consensus target price of $34.00, suggesting a potential upside of 63.38%. Given Bioventus' stronger consensus rating and higher possible upside, equities research analysts plainly believe Bioventus is more favorable than Sanara MedTech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bioventus	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	3.00
Sanara MedTech	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Bioventus has a beta of 0.67, indicating that its stock price is 33% less volatile than the broader market. Comparatively, Sanara MedTech has a beta of 1.21, indicating that its stock price is 21% more volatile than the broader market.

62.9% of Bioventus shares are owned by institutional investors. Comparatively, 8.1% of Sanara MedTech shares are owned by institutional investors. 33.0% of Bioventus shares are owned by company insiders. Comparatively, 42.0% of Sanara MedTech shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, Bioventus and Bioventus both had 4 articles in the media. Sanara MedTech's average media sentiment score of 1.19 beat Bioventus' score of 1.00 indicating that Sanara MedTech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bioventus	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Sanara MedTech	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Bioventus has higher revenue and earnings than Sanara MedTech. Sanara MedTech is trading at a lower price-to-earnings ratio than Bioventus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bioventus	$568.09M	1.25	$22.73M	$0.41	20.76
Sanara MedTech	$103.12M	1.85	-$37.56M	-$3.77	N/A

Summary

Bioventus beats Sanara MedTech on 12 of the 16 factors compared between the two stocks.

How does Sanara MedTech compare to SS Innovations International?

Sanara MedTech (NASDAQ:SMTI) and SS Innovations International (NASDAQ:SSII) are both small-cap medical equipment companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, profitability, media sentiment, dividends, risk, valuation, earnings and institutional ownership.

Sanara MedTech presently has a consensus target price of $34.00, suggesting a potential upside of 63.38%. SS Innovations International has a consensus target price of $7.00, suggesting a potential upside of 108.33%. Given SS Innovations International's higher possible upside, analysts plainly believe SS Innovations International is more favorable than Sanara MedTech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sanara MedTech	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
SS Innovations International	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Sanara MedTech has a beta of 1.21, indicating that its stock price is 21% more volatile than the broader market. Comparatively, SS Innovations International has a beta of -1.89, indicating that its stock price is 289% less volatile than the broader market.

In the previous week, Sanara MedTech had 2 more articles in the media than SS Innovations International. MarketBeat recorded 4 mentions for Sanara MedTech and 2 mentions for SS Innovations International. Sanara MedTech's average media sentiment score of 1.19 beat SS Innovations International's score of 1.16 indicating that Sanara MedTech is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sanara MedTech	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
SS Innovations International	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

SS Innovations International has lower revenue, but higher earnings than Sanara MedTech. SS Innovations International is trading at a lower price-to-earnings ratio than Sanara MedTech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sanara MedTech	$103.12M	1.85	-$37.56M	-$3.77	N/A
SS Innovations International	$42.49M	15.83	-$12.13M	-$0.05	N/A

8.1% of Sanara MedTech shares are held by institutional investors. 42.0% of Sanara MedTech shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

SS Innovations International has a net margin of -20.69% compared to Sanara MedTech's net margin of -31.23%. Sanara MedTech's return on equity of -3.19% beat SS Innovations International's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sanara MedTech	-31.23%	-3.19%	-0.56%
SS Innovations International	-20.69%	-23.00%	-13.18%

Summary

Sanara MedTech beats SS Innovations International on 11 of the 16 factors compared between the two stocks.

How does Sanara MedTech compare to CeriBell?

Sanara MedTech (NASDAQ:SMTI) and CeriBell (NASDAQ:CBLL) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, risk, earnings, media sentiment, dividends and valuation.

Sanara MedTech has higher revenue and earnings than CeriBell. CeriBell is trading at a lower price-to-earnings ratio than Sanara MedTech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sanara MedTech	$103.12M	1.85	-$37.56M	-$3.77	N/A
CeriBell	$89.06M	7.87	-$53.41M	-$1.63	N/A

Sanara MedTech has a beta of 1.21, meaning that its share price is 21% more volatile than the broader market. Comparatively, CeriBell has a beta of 0.85, meaning that its share price is 15% less volatile than the broader market.

Sanara MedTech has a net margin of -31.23% compared to CeriBell's net margin of -63.51%. Sanara MedTech's return on equity of -3.19% beat CeriBell's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sanara MedTech	-31.23%	-3.19%	-0.56%
CeriBell	-63.51%	-38.19%	-30.92%

Sanara MedTech currently has a consensus target price of $34.00, indicating a potential upside of 63.38%. CeriBell has a consensus target price of $22.20, indicating a potential upside of 20.19%. Given Sanara MedTech's higher probable upside, equities analysts plainly believe Sanara MedTech is more favorable than CeriBell.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sanara MedTech	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
CeriBell	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83

In the previous week, CeriBell had 1 more articles in the media than Sanara MedTech. MarketBeat recorded 5 mentions for CeriBell and 4 mentions for Sanara MedTech. Sanara MedTech's average media sentiment score of 1.19 beat CeriBell's score of 0.56 indicating that Sanara MedTech is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sanara MedTech	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
CeriBell	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

8.1% of Sanara MedTech shares are held by institutional investors. 42.0% of Sanara MedTech shares are held by company insiders. Comparatively, 20.1% of CeriBell shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Sanara MedTech beats CeriBell on 11 of the 17 factors compared between the two stocks.

How does Sanara MedTech compare to SiBone?

SiBone (NASDAQ:SIBN) and Sanara MedTech (NASDAQ:SMTI) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, institutional ownership, risk, earnings, analyst recommendations, dividends, media sentiment and profitability.

SiBone has higher revenue and earnings than Sanara MedTech. SiBone is trading at a lower price-to-earnings ratio than Sanara MedTech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SiBone	$200.93M	3.40	-$18.90M	-$0.39	N/A
Sanara MedTech	$103.12M	1.85	-$37.56M	-$3.77	N/A

SiBone has a beta of 0.7, indicating that its stock price is 30% less volatile than the broader market. Comparatively, Sanara MedTech has a beta of 1.21, indicating that its stock price is 21% more volatile than the broader market.

SiBone has a net margin of -8.10% compared to Sanara MedTech's net margin of -31.23%. Sanara MedTech's return on equity of -3.19% beat SiBone's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SiBone	-8.10%	-9.56%	-7.06%
Sanara MedTech	-31.23%	-3.19%	-0.56%

In the previous week, Sanara MedTech had 1 more articles in the media than SiBone. MarketBeat recorded 4 mentions for Sanara MedTech and 3 mentions for SiBone. Sanara MedTech's average media sentiment score of 1.19 beat SiBone's score of 0.60 indicating that Sanara MedTech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
SiBone	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Sanara MedTech	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

SiBone currently has a consensus price target of $23.00, suggesting a potential upside of 49.16%. Sanara MedTech has a consensus price target of $34.00, suggesting a potential upside of 63.38%. Given Sanara MedTech's higher probable upside, analysts plainly believe Sanara MedTech is more favorable than SiBone.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SiBone	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Sanara MedTech	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

98.1% of SiBone shares are held by institutional investors. Comparatively, 8.1% of Sanara MedTech shares are held by institutional investors. 3.9% of SiBone shares are held by company insiders. Comparatively, 42.0% of Sanara MedTech shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

SiBone and Sanara MedTech tied by winning 8 of the 16 factors compared between the two stocks.

How does Sanara MedTech compare to Beta Bionics?

Sanara MedTech (NASDAQ:SMTI) and Beta Bionics (NASDAQ:BBNX) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, earnings, valuation, analyst recommendations, media sentiment, dividends, profitability and risk.

Sanara MedTech has a net margin of -31.23% compared to Beta Bionics' net margin of -60.27%. Sanara MedTech's return on equity of -3.19% beat Beta Bionics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sanara MedTech	-31.23%	-3.19%	-0.56%
Beta Bionics	-60.27%	-23.00%	-20.55%

Sanara MedTech has a beta of 1.21, indicating that its stock price is 21% more volatile than the broader market. Comparatively, Beta Bionics has a beta of 3.4, indicating that its stock price is 240% more volatile than the broader market.

In the previous week, Beta Bionics had 2 more articles in the media than Sanara MedTech. MarketBeat recorded 6 mentions for Beta Bionics and 4 mentions for Sanara MedTech. Sanara MedTech's average media sentiment score of 1.19 beat Beta Bionics' score of 0.22 indicating that Sanara MedTech is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sanara MedTech	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Beta Bionics	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

8.1% of Sanara MedTech shares are held by institutional investors. 42.0% of Sanara MedTech shares are held by company insiders. Comparatively, 5.3% of Beta Bionics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Sanara MedTech has higher revenue and earnings than Beta Bionics. Beta Bionics is trading at a lower price-to-earnings ratio than Sanara MedTech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sanara MedTech	$103.12M	1.85	-$37.56M	-$3.77	N/A
Beta Bionics	$100.25M	6.46	-$73.20M	-$1.51	N/A

Sanara MedTech currently has a consensus price target of $34.00, suggesting a potential upside of 63.38%. Beta Bionics has a consensus price target of $19.70, suggesting a potential upside of 35.58%. Given Sanara MedTech's higher possible upside, research analysts clearly believe Sanara MedTech is more favorable than Beta Bionics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sanara MedTech	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Beta Bionics	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.64

Summary

Sanara MedTech beats Beta Bionics on 10 of the 17 factors compared between the two stocks.

Get Sanara MedTech News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SMTI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SMTI vs. The Competition

Export

Metric	Sanara MedTech	MED PRODUCTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$190.62M	$8.31B	$6.53B	$12.05B
Dividend Yield	N/A	2.50%	2.67%	5.67%
P/E Ratio	-5.52	15.64	24.22	24.42
Price / Sales	1.85	7.06	511.60	109.90
Price / Cash	35.00	17.44	27.48	37.92
Price / Book	31.06	3.62	10.65	6.82
Net Income	-$37.56M	$224.06M	$3.57B	$337.56M
7 Day Performance	-5.79%	-1.40%	0.58%	1.17%
1 Month Performance	-1.19%	4.39%	1.54%	3.16%
1 Year Performance	-27.77%	-0.88%	25.40%	30.58%

Sanara MedTech Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SMTI Sanara MedTech	2.1114 of 5 stars	$20.81 flat	$34.00 +63.4%	-27.8%	$190.62M	$103.12M	N/A	60	Positive News Gap Up
BVS Bioventus	4.4627 of 5 stars	$9.15 -0.6%	$14.00 +53.1%	N/A	$763.56M	$568.09M	22.29	1,200	Positive News Gap Up
SSII SS Innovations International	2.9162 of 5 stars	$3.64 +2.1%	$7.00 +92.6%	-5.1%	$727.47M	$42.49M	N/A	4	News Coverage Positive News
CBLL CeriBell	2.3784 of 5 stars	$18.41 -0.5%	$22.20 +20.6%	+6.9%	$696.20M	$89.06M	N/A	N/A
SIBN SiBone	2.3093 of 5 stars	$15.65 +0.8%	$23.00 +47.0%	-11.5%	$693.37M	$200.93M	N/A	350

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SMTI) was last updated on 6/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Sanara MedTech (SMTI) Competitors

SMTI vs. BVS, SSII, CBLL, SIBN, and BBNX

How does Sanara MedTech compare to Bioventus?

Summary

How does Sanara MedTech compare to SS Innovations International?

Summary

How does Sanara MedTech compare to CeriBell?

Summary

How does Sanara MedTech compare to SiBone?

Summary

How does Sanara MedTech compare to Beta Bionics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SMTI vs. The Competition

Sanara MedTech Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Sanara MedTech (SMTI) Competitors

SMTI vs. BVS, SSII, CBLL, SIBN, and BBNX

How does Sanara MedTech compare to Bioventus?

Is BVS or SMTI more profitable?

Do analysts rate BVS or SMTI?

Which has more volatility & risk, BVS or SMTI?

Do institutionals and insiders hold more shares of BVS or SMTI?

Does the media favor BVS or SMTI?

Which has preferable valuation & earnings, BVS or SMTI?

Summary

How does Sanara MedTech compare to SS Innovations International?

Do analysts prefer SMTI or SSII?

Which has more risk and volatility, SMTI or SSII?

Does the media refer more to SMTI or SSII?

Which has higher earnings and valuation, SMTI or SSII?

Do insiders & institutionals hold more shares of SMTI or SSII?

Is SMTI or SSII more profitable?

Summary

How does Sanara MedTech compare to CeriBell?

Which has stronger valuation and earnings, SMTI or CBLL?

Which has more volatility and risk, SMTI or CBLL?

Is SMTI or CBLL more profitable?

Do analysts rate SMTI or CBLL?

Does the media refer more to SMTI or CBLL?

Do insiders and institutionals believe in SMTI or CBLL?

Summary

How does Sanara MedTech compare to SiBone?

Which has better earnings & valuation, SIBN or SMTI?

Which has more volatility and risk, SIBN or SMTI?

Is SIBN or SMTI more profitable?

Does the media favor SIBN or SMTI?

Do analysts prefer SIBN or SMTI?

Do insiders & institutionals have more ownership in SIBN or SMTI?

Summary

How does Sanara MedTech compare to Beta Bionics?

Is SMTI or BBNX more profitable?

Which has more risk and volatility, SMTI or BBNX?

Does the media refer more to SMTI or BBNX?

Do insiders & institutionals have more ownership in SMTI or BBNX?

Which has preferable earnings and valuation, SMTI or BBNX?

Do analysts prefer SMTI or BBNX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SMTI vs. The Competition

Sanara MedTech Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools